Source comparison
Sermorelin vs HGH Therapy Mechanism: Side-by-Side Comparison
Site of Action Anterior pituitary GHRH receptors Peripheral GH receptors (liver, muscle, adipose) Sermorelin requires functional pituitary; HGH works regardless of pituitary status GH Secretion Pattern Pulsatile (physiological rhythm preserved) Sustained eleva
This comparison does not assign a generated winner or score.
- Site of Action
- Anterior pituitary GHRH receptors
- Peripheral GH receptors (liver, muscle, adipose)
- Sermorelin requires functional pituitary; HGH works regardless of pituitary status
- GH Secretion Pattern
- Pulsatile (physiological rhythm preserved)
- Sustained elevation (non-physiological)
- Sermorelin maintains circadian peaks; HGH creates continuous exposure
- IGF-1 Profile
- Gradual increase to mid-normal range (150–250 ng/mL)
- Rapid increase to upper-normal or supraphysiological range (300–500+ ng/mL)
- Sermorelin avoids IGF-1 spikes that trigger negative feedback
- Hypothalamic Feedback
- Intact. Somatostatin still regulates pulses
- Suppressed. Elevated IGF-1 reduces endogenous GH
- Sermorelin preserves natural axis function; HGH suppresses it
- Discontinuation Recovery
- Baseline GH secretion returns in 2–4 weeks
- Endogenous GH recovery takes 8–16+ weeks; may be incomplete
- Sermorelin has no rebound suppression; HGH creates dependency risk
- Regulatory Classification
- Prescription peptide; off-label use common in wellness
- Schedule III controlled substance; FDA-approved for specific deficiencies only
- HGH requires documented GHD diagnosis; sermorelin has broader prescribing latitude